Related Experiment Videos
Treatment of hypertension: a clinical epidemiologist's view
1Department of Community Medicine, UCMSM, London, U.K.
Insights
Hypertension management aims to prevent coronary artery disease (CAD) deaths. Current treatments using diuretics and beta-blockers show limited CAD benefit, suggesting a need for metabolically favorable alternatives.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Hypertension significantly contributes to coronary artery disease (CAD) mortality.
- Despite blood pressure reduction, clinical trials show suboptimal CAD event and mortality prevention.
- Existing hypertension management strategies may be insufficient for comprehensive CAD risk reduction.
Purpose of the Study:
- To evaluate the effectiveness of current hypertension management in preventing CAD.
- To investigate the impact of commonly used antihypertensive drugs on CAD risk factors.
- To advocate for alternative antihypertensive agents with improved metabolic profiles.
Main Methods:
- Review of recent meta-analyses of hypertension intervention trials.
- Analysis of drug classes used in trials, focusing on thiazide diuretics and beta-blockers.
- Examination of the effects of these drug classes on lipid profiles and other metabolic risk factors for CAD.
Main Results:
- Trials using thiazide diuretics and beta-blockers demonstrated a shortfall in expected CAD event and mortality prevention.
- Thiazide diuretics and beta-blockers negatively impact lipid profiles, a key CAD risk factor.
- These drugs also adversely affect glucose metabolism, insulin resistance, potassium, and uric acid levels, further influencing CAD incidence.
Conclusions:
- The suboptimal CAD prevention observed in trials may stem from the adverse metabolic effects of commonly used antihypertensives.
- A shift towards antihypertensive agents with more favorable metabolic profiles is warranted for effective hypertension and CAD management.
- Future hypertension management should prioritize drugs that mitigate, rather than exacerbate, cardiovascular risk factors.
Abstract:
The majority of deaths attributable to hypertension are coronary artery disease (CAD) deaths and, consequently, the prevention of CAD should be the primary aim of hypertension management. Recent meta-analyses confirm the results of the individual hypertension intervention trials, which demonstrated a disappointing shortfall in the observed prevention of CAD events and mortality from lowering blood pressure compared with the expected benefits. These trial results, rather than challenging the validity of the causal nature of the association between hypertension and CAD may be interpreted to suggest that the management of hypertension in the trials was suboptimal. The drugs used in the trials were almost exclusively thiazide diuretics and to a lesser extent beta-blockers. Both of these drug groups have been shown to have adverse effects on lipid profiles--a pivotal risk factor for CAD. In addition to the effects on lipids, diuretics also adversely affect potassium, uric acid, glucose metabolism, and insulin resistance, all of which directly or indirectly affect the incidence of CAD. In the face of a major shortfall in the overall benefit from managing hypertension with diuretics and to a lesser extent beta-blockers, it therefore seems more logical to recommend for the management of hypertension the use of agents with a more metabolic-friendly profile.